Johns Hopkins HIV Guide
Elvitegravir
INDICATIONS
FDA
FDA
- Treatment of HIV infection as part of a single-tablet regimen (e.g., Stribild, Genvoya) for adults who are ART-naive or to replace a stable regimen in patients who are virologically suppressed
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HIV infection for adults who are ARV-experienced but not virologically suppressed on a stable regimen
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 13, 2023
Citation
Auwaerter, Paul G, and Paul A Pham. "Elvitegravir." Johns Hopkins HIV Guide, The Johns Hopkins University, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/all/Elvitegravir.
Auwaerter PG, Pham PA. Elvitegravir. Johns Hopkins HIV Guide. The Johns Hopkins University; 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/all/Elvitegravir. Accessed October 31, 2025.
Auwaerter, P. G., & Pham, P. A. (2023). Elvitegravir. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/all/Elvitegravir
Auwaerter PG, Pham PA. Elvitegravir [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2023. [cited 2025 October 31]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/all/Elvitegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Elvitegravir
ID - 545235
A1 - Auwaerter,Paul,M.D.
AU - Pham,Paul,Pharm.D. BCPS
Y1 - 2023/08/13/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/all/Elvitegravir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
